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DIFFERENTIAL EFFECTS OF GLYCOGEN SYNTHASE KINASE 3 
INHIBITORS ON MIGRATION IN GLIOBLASTOMA CELL LINES 
 
SHREYAS MAHAPATRA 
ABSTRACT 
Glioblastoma multiforme (GBM) represents the deadliest brain cancer pathology. 
Current therapeutic treatment focuses on surgical resection of tumors, followed by 
adjuvant radiation and/or chemotherapy. The invasive nature of GBM however limits the 
effectiveness of such therapy.  
Drug development for GBM has centered on attempts to manage this infiltrative 
capacity. One avenue of such development focuses on aberrant cellular signaling 
pathways characteristic of malignancies. This study sought to understand the mechanism 
by which glycogen synthase kinase 3 (GSK-3) inhibitors differentially regulate GBM 
migration. Measurement of in vitro cellular migration has traditionally utilized Boyden 
chamber (transwell) assays and collagen migration assays. Administration of known 
GSK-3 inhibitors demonstrate a differential effect, whereby migration is inhibited in 
transwell assays, but maintained in the collagen assay. Cell aggregates from 4 different 
GBM cell lines were utilized in comparison of GSK-3 inhibitor effects in both the 
transwell and collagen assays. Contrary to previous findings, GSK-3 inhibitors 
demonstrated limited effect in reducing migration in the transwell assay, while 
demonstrating modest effects in the collagen assay. 
  vi 
A mechanistic understanding of GSK-3 inhibitor function remains elusive. 
Previous studies have demonstrated GSK-3 effects on various cytoskeletal proteins, 
including the WAVE-2 complex, vital for cytoskeletal stability. Administration of GSK-3 
inhibitors had previously led to a downregulation of WAVE2 levels. After administration 
of known GSK-3 inhibitors, this study failed to reproduce previous differences in total 
WAVE2 protein levels compared to control untreated samples. This evidence indicates a 
different mode of cytoskeletal regulation must be driving GSK-3 inhibition’s effect on 
GBM migration. 
GSK-3 inhibitors represent one promising class of chemotherapeutic agents for 
treatment of GBM. This study corroborated previous findings about the effect of classical 
GSK-3 inhibitors (BIO, CHI99021) in reducing GBM migration. Further investigation is 
necessary to isolate the specific cellular mechanisms responsible for GSK-3’s effects. 
With rapid development of other therapeutic strategies, GSK-3 inhibitors present one 
class of drugs available to clinicians for effective therapeutic management of GBM. 
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INTRODUCTION 
 
 Glioblastoma multiforme (GBM) is a primary brain cancer and represents one of 
the most clinically challenging malignancies of the brain. The earliest mention of GBM 
in the scientific literature dates back to 1929, where Dr. R. C. Buckley characterized 
tumor isolates using a “hanging drop” method (Buckley, 1929). Median survival times 
are currently estimated at 15 months, with a 2-year survival rate of 30% (American Brain 
Tumor Association). Current therapy includes initial exploratory surgery and tumor 
resection, followed by treatment with radiation and/or chemotherapy. GBM is 
differentiated many from other brain cancers by the presence of rapidly infiltrating cells. 
This invasion renders traditional surgical resection ineffective in reducing recurrence or 
metastatic risk.  
The general therapeutic strategy for GBM treatment has remained largely 
unchanged over the subsequent many decades, with primary tumor excision, followed by 
either radiotherapy and/or chemotherapy. A variety of chemotherapeutic agents trialed in 
vitro for GBM therapy have spanned a range of functions. Certain compounds have acted 
as radiosensitizers, enhancing the effectiveness of radiotherapy (Hau et al., 2016). 
Classical chemotherapeutic agents such as Cisplatin have also been trialed and have 
demonstrated moderate effects (Stewart et al., 1984).  Aberrant signaling pathway 
activation has become accepted as a hallmark of cancer biology. As such, 
chemotherapeutic agents have aimed to target specific cell signaling pathways vital for 
cell proliferation and motility.  
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Amongst signaling pathways studied, glycogen synthase kinase 3 beta (GSK-3β) 
has been observed as a key master regulatory enzyme in multiple pathways and 
processes. GSK-3β is a serine/threonine kinase that was discovered based on its ability to 
phosphorylate and inhibit glycogen synthase and promote synthesis of glycogen.   Since 
its discovery, GSK-3β has been implicated in a variety of roles including neuronal cell 
development, inflammation, cell polarity, and energy metabolism (Atkins et al., 2013).  
Aberrant constitutive activation of receptor tyrosine kinases (RTKs) often results in 
downstream inactivation of GSK-3β. Its diversity of function centers on GSK-3β’s key 
role in the Wnt/β-catenin and phosphoinositide-3-kinase (PI3-K) pathways. As 
invasiveness remains one of the distinguishing and pathologic features of GBM, there is 
particular interest in GSK-3β’s role in cell cytoskeletal structure and motility.  
Early application of GSK-3 inhibitors, including lithium, resulted in diminished 
migratory capability of GBM cell lines (Nowicki et al., 2008, Fu et al., 2014). The 
mechanism by which GSK-3 inhibitors acted, remains unknown. Tumor invasion has 
been empirically studied utilizing two different experimental paradigms: Boyden 
(transwell) assay and collagen migration assays. Transwell assays depend on the ability 
of a cell to squeeze through a small pore in a memebrane. The observed reduced 
migration indicates the possible effect of contractility elements in invasiveness. By 
contrast, collagen assays recapitulate, to an extent, the matrix of the tumor 
microenvironment. Preliminary evidence has indicated selective GSK-3 inhibitors serve 
to reduce GBM motility in the transwell assay, but fail to do so in the collagen assay. 
This differential effect may be caused by specific cell-environment interactions taking 
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place in the collagen assay that are absent in the transwell setup. Alternatively, GSK-3 
inhibitors may specifically act on a cytoskeletal element crucial for the cell body 
compaction required for successful passage through transwell pores. Selectivity of GSK-
3 inhibition may also contribute to differences in migration. Investigation into the 
molecular mechanisms of cell motility may reveal how GSK-3 inhibitors are capable of 
reducing tumor migration.  Development of such agents may represent a key advance in 
chemotherapeutic management of GBM. 
 
Specific Aims 
 GSK-3 inhibitors have shown promise in reducing GBM migration and invasion. 
Differences between GBM migration in transwell and collagen assays have been 
observed. Previous research indicates a reduction of migration of GBM cell lines in the 
transwell assay that is not recapitulated in the collagen assay. This study sought to clarify 
the cause of this difference as well as define a functional mechanism of GSK-3β 
inhibition and its primary effect on cell motility.  
Utilizing a panel of known GSK-3 inhibitors, cell toxicity studies were initially 
carried out 4 GBM cell lines: G9, G30, G68, and U251. Comparison of selective GSK-3 
inhibitors vs non-selective GSK-3 inhibitor BIO may indicate specificity of GSK-3 alpha 
or beta in reducing migration. In order to confirm previous findings about the differential 
effects of GSK-3 inhibitor treatment of GBM cell lines in the transwell and collagen 
assays, both assays were carried out in each cell line.  
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The mechanism by which GSK-3 inhibitors reduce migration remains unclear. GSK-3 
inhibition may lead to cytoskeletal dysregulation via inhibition of the WAVE2 protein 
complex. In parallel GBM cells may successfully invade in the collagen assay due to the 
activity of matrix metalloproteinases (MMP) and subsequent enhancement of integrin 
binding and recycling. Western blotting of cell lysates was conducted with an antibody 
specific to WAVE2.   
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METHODS  
 
 Cell Lines and Reagents 
Human glioblastoma cell lines used in this study were as follows: U251 was 
purchased from ATCC, and G9, G68, and G30 obtained from The Ohio State University 
(OSU). Established protocols approved by the Institutional Research Board were used by 
the OSU tissue procurement facility to acquire human tissue.  
Marker vector copGFP (System Biosciences, empty pCDH lentiviral vector) was 
used for transfection in U251, G9, G68, and G30 cell lines. U251 pCDH cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen,Carlsbad, CA, 
USA) with 10% fetal bovine serum (FBS). G9, G68 and G30 pCDH cell lines were 
cultured in neurobasal medium (Life Technologies, Grand Island, NY, USA) and 
supplemented with B27, epidermal growth factor (EGF), and fibroblast growth factor 
(FGF). EGF and FGF (Peprotech, Rocky Hill, NJ, USA) were added at 10ng/mL. All 
cells were maintained in culture at 37ºC with 5% CO2.  
 Dimethyl sulfoxide (DMSO) was used as a solvent for all compounds and a 
negative control for all assays. CHIR99021, BIO, AZD1080, and AZD2858, known 
GSK-3 inhibitors, were obtained from Tocris and tested in all assays. Additionally, 
Tideglusib and Temozolomide (TMZ), two drugs with potential GSK-3 inhibitory 
activity were compared. 
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Growth in Low Attachment (GILA) Assay 
 To measure cell viability and cytotoxic effects of GSK-3 inhibitors, 2,000 cells 
were cultured 96-well ultra low attachment round bottom plates in 200 uL of DMEM 
media with 10% FBS. 24 hours after plating, 100 uL of drug were added to each well and 
images were captured. Images were taken every 24 hours for a period of 120 hours post 
treatment. Total area measurements were calculated from images. 
 
Collagen Spheroid Assay 
Three-dimensional spheroid cultures were produced by allocation of 1,000 cells in 
96-well ultra low attachment plates in either DMEM with 10% FBS (U251 cell line) or 
neurobasal medium with growth factors and b27 (G9, G8, and G30 cell lines). To induce 
spheroid formation, aggregates were grown in minimal (10 uL/well) medium conditions. 
After stable sphere formation, 40μl neutralized collagen I solution (PureCol, Inamed, 
Fremont, CA, USA) was added to each well. Collagen was neutralized to pH 7.5 using 
1N NaOH and 0.5X DMEM for U251 cell line, and 0.5X neurobasal medium for G9, 
G68, and G30 cell lines. The collagen I solution polymerized into a gel at 38ºC. Medium 
(50μl) with drugs (2x concentration) was added on top of the collagen I. Spheroid area 
was recorded up to 96 hours using a Nikon TE2000 microscope system with on-stage 
incubation.  
 
Transwell Assay 
 7 
96-well plates with 8 uM pore size (VWR, Randor, PA) were used. U251, G68, 
G9, or G30 cells grown in DMEM supplemented with 10% FBS and were counted and 
allotted at 10,000 cells/well. Cells were incubated with appropriate amount of selected 
treatment (AZD1080, AZD2858, BIO, CHIR99021, DMSO, Tideglusib, TMZ, SB41). 
The bottom chamber of plate was allotted media with treatment as well. Cells were 
transferred to the insert and permitted to migrate while being monitored using a Nikon 
TE2000 microscope system with on-stage incubation for live-cell imaging.  
 
Western Blotting 
 Cells were grown to 80% confluency in a 6 well plate with appropriate treatments 
at 10 uM concentration. Tris-HCL lysis buffer was used at 10 uL/well to collect whole 
protein lysate. Bradford assay was utilized to determine protein concentration for gel 
loading. Pre-cast Mini-PROTEAN tris-glycine gels were utilized for gel electrophoresis 
(Bio-Rad, Hercules, CA), followed by transfer onto PVDF membrane. The membrane 
was interrogated with a rabbit anti WAVE2 antibody (Cell Signaling, Danvers, MA), 
followed by horseradish peroxidase-conjugated goat anti rabbit secondary antibody. 
Membranes were visualized using a Pierce ECL western blotting substrate (Thermo 
Scientific, Rockford, IL). 
 8 
Statistical Analyses 
 All image processing was performed using ImageJ, and all statistical analysis was 
done in Microsoft Excel. Significance was determined using a two-tailed students t-test 
from averages and standard deviations computed using Excel. 
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RESULTS 
 
 
 Growth in Low Attachment (GILA) Assay 
The GILA assay was utilized to assess cell survival and tolerance of treatment. 
Comparison of cell viability utilizing the GILA assay demonstrated differential effects 
for the compounds of interest.  
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Figure 1. GILA area measurements after treatment of G30 pCDH cells with GSK-3 inhibitor panel 
and control DMSO This exemplary GILA data set demonstrates the largely limited cytotoxic effect 
experienced by G30 pCDH cell lines across the 1.25-10 μM dosage range for the GSK-3 inhibitors. 
 
 Cytotoxic effects appear as large decreases in measured area with increasing 
concentrations of drug. Figure 1 summarizes GILA data from G30 pCDH cell aggregates 
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treated with GSK-3 inhibitors. Among the GSK-3 inhibitor panel, BIO, AZD 1080, and 
AZD 2858 tended to demonstrate cytotoxic effects at higher concentrations (5 and 10 
μM). Although differences did not reach significance in G30 pCDH, G68 pCDH, or 
U251 pCDH cells, significant differences were observed in G9 pCDH cells at 120 hours 
post-treatment. Figure 2 demonstrates this dose-dependent change in total area observed 
in the G9 pCDH cells. Such effects, being focused on late time points, may have largely 
been driven resource-depletion driven cell death. See Appendix A for full GILA figure 
set for G9 pCDH cells. Taken together, these results corroborate pervious findings of 
general tolerance of GSK-3 inhibitors in vitro.  
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Figure 2. Selected GILA area plots for G9 pCDH cells treated with AZD 2858, and Bio, respectively 
Significant differences (p < 0.05) in total area were demonstrated in the AZD 2858 and Bio 0.08 uM vs 10 
uM groups at 120 hours post-treatment. 
 
Collagen Spheroid Assay 
 Collagen assays were conducted for all 4 cell lines utilizing the same GSK-3 
inhibitor panel. Figure 3 shows an example of images from a collagen assay from a 
different study. 
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Figure 3. Example images of collagen spheroid assay after treatment with select GSK-3 inhibitors 
(Rolfs, 2016) 
 
After 3 trials, G30 pCDH and U251 pCDH aggregates failed to satisfactorily migrate in 
the collagen assay. Total area measurements were recorded across multiple time points 
for G30 pCDH and G68 pCDH. Figure 4 depicts total area data for G30 pCDH 
aggregates. Across treatments, the GSK-3 inhibitor panel demonstrated modest reduction 
in area compared to control DMSO cell aggregates. Bio and CHIR99021 yielded 
statistically significant reductions at 10 μM compared to control. 
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Figure 4. Total Area plots from collagen spheroid assay of G9 pCDH cells 
 
Transwell Assay 
 Transwell assays were attempted in all four cell lines. G30 pCDH cell aggregates 
failed to migrate in the transwell assay and were excluded from this analysis. G68 pCDH 
and U251 pCDH total area data are summarized in Figure 4 and 5, respectively. In 
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neither cell line were there significant differences in total area in the treatment groups vs 
control DMSO aggregates. An extended length time lapse was carried out on G9 pCDH 
aggregates over 96 hours. These results are displayed as area measurements in Figure 6. 
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Figure 5. Total Area Measurements for G68 pCDH Transwell Assay Total area measurements were 
collected on the post-membrane surface over a 42 hour time lapse. 
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Figure 6. Total Area Measurements for U251 pCDH Transwell Assay As in Figure 4, total area 
measurements were collected over a 50 hour time lapse  
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Figure 7. Time Lapse Total Area Measurements on G9 pCDH aggregates in Transwell Assay 
 
Western Blotting 
 In order to test the hypothesis that WAVE2 regulation played a role in GSK-3 
inhibition of migration, Western blotting on U251 pCDH cell lysates was conducted. 
Figure 7 depicts the blotting result. Table 1 provides the setup of the gel visualized in 
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Figure 7. No significant difference between control DMSO and treated cells in WAVE 2 
concentration (determined by band intensity) was observed. 
 
Lane   Drug Concentration 
1 AZD 1080 10 uM 
2 AZD 2858 10 uM 
3 Bio 10 uM 
4 Chi 10 uM 
5 DMSO 10 uM 
6 Tide 10 uM 
7 TMZ 10 uM 
8 SB41 10 uM 
Table 1. Outline of WAVE2 blot setup Lanes numbered from left to right on picture 
 
 
Figure 8. Picture of WAVE2 western blot U251 pCDH cell lysates were interrogated with a goat anti 
WAVE2 antibody and visualized using a rabbit anti goat secondary antibody 
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DISCUSSION 
 
 The primary goal of this study was the evaluation of the differential effects of 
GSK-3 inhibitors in migration of glioblastoma cell lines. Previous evidence had indicated 
GSK-3 inhibitors serve to inhibit migration in the transwell assay, but fail to do so in the 
collagen assay. Further, this studied aimed to develop a mechanistic understanding for 
this differential effect. 
 In comparison to control DMSO cell aggregates, none of the tested GSK-3 
inhibitors demonstrated significant reductions in total area in the transwell assay. This is 
in direct opposition to previous findings in the same dosage range indicting the 
preliminary effectiveness of GSK-3 inhibitors in reducing migration in the transwell 
assay. GILA assay results indicate that cells are tolerant to treatment with the GSK-3 
inhibitor panel.  The limited effect of GSK-3 inhibitors in GBM migration calls into 
question the molecular pathways central to their mode of action. Further investigation 
will be necessary to confirm these effects. 
  Utilizing the collagen assay, GSK-3 inhibitors demonstrated generally 
limited reductions in migration across cell lines. The most robust inhibition was observed 
in CHIR99021 and BIO treatment groups. As two classical GSK-3 inhibitors, these 
results are in line with previous literature indicating the potency of BIO and CHIR99021. 
In comparison to selective GSK-3 inhibitors, BIO, a nonselective GSK-3 inhibitor, 
resulted in more potent inhibition of migration in the collagen assay. These results may 
indicate that GSK-3-linked effects on migration are not selective to the isoform of GSK-3 
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involved. Further study is required to confirm this finding and understand the cause of 
reduced migration. 
 Nonetheless, the observed reduced migration in the collagen assay, combined with the 
limited inhibition seen in the transwell assay, are in direct opposition to previous 
findings.  
 One potential mechanism of GSK-3 action is via inhibition of Rac1, a RAS 
GTPase. Downstream effectors of Rac1 include WAVE2, a known regulator of actin 
structural integrity (Yoshino et al, 2015). WAVE2 acts via activation of the Arp2/3 
complex, responsible for both nucleation of new actin filaments as well as branching of 
existing actin filaments (Millard et al., 2004). Downregulation of WAVE2 by GSK-3 
inhibitors would serve to jeopardize general actin integrity and undermine migration in 
cancer cell lines. Western blotting carried out for WAVE2 after a fifteen-minute 
incubation with the GSK-3 inhibitor panel indicated no such differences in WAVE2 
concentrations in treated vs. control cell lines. These results may be attributed to rapid 
and reversible inhibition of WAVE2 by the inhibitors, a time scale not captured by 
interrogation with antibodies. Alternatively, the mechanistic features of GSK-3 inhibition 
of migration may not directly involve WAVE2 but instead other key regulators of 
cytoskeletal integrity such as phosphatidyl inositol 3 kinase (PI3K)/Akt/GSK-3 pathway. 
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APPENDIX A. G9 pCDH GILA Data 
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